A group of private investors led by drug development executive An LuFan have seeded a fund to drive healthcare research from South Australia's academic sector.
Adelaide China Biotech Investment Fund officially debuted yesterday with $45m in capital to back biotech research from South Australia-based institutions including University of Adelaide and University of South Australia (UniSA).
The funding comes from a group of private investors led by An LuFan, the executive director of China-based drug developer D&R Pharmaceuticals.
Adelaide China Biotech aims to drive pharmaceutical and clinical diagnostics research at South Australia’s universities, hospitals and research institutions.
The fund has earmarked $5m to…
